American BioMed, Inc. Receives Japanese Ministry of Health Approval and Signs German Distributor
THE WOODLANDS, Texas, Dec. 22 /PRNewswire/ -- American BioMed, Inc. (OTC Bulletin Board: ABMI - news), today announced that PFM of Cologne, Germany has joined American BioMed's expanding global distribution network. In addition American BioMed announced that they have received Ministry of Health approval in Japan opening the way for full scale promotion in that country of its silicone balloon catheter product line.
PFM is a major manufacturer and distributor of vascular and cardiovascular products to the German market. PFM also has branch offices throughout Europe and Asia. PFM has placed initial stocking orders and training began in November.
Marshall Kerr, Vice President of Sales and Marketing of American BioMed stated, ''The addition of PFM gives American BioMed a key distributor in the important German medical market. With this addition we have distributors strategically located in the key markets in Europe. We will continue to search for and add quality distributors, specifically in Eastern Europe and the Middle East.''
With the awarding of Japan's Ministry of Health registration Medical Leaders of Japan can now launch full-scale promotion of American BioMed's balloon catheter products. Orders have been placed to support large-scale promotion. Medical Leaders continue to seek approval of American BioMed's OmniCath® Atherectomy product. Commenting further, ''our domestic distributors continue to convert their hospitals to American BioMed products. The interest in our Silicone Embolectomy
Catheters continues to be strong as the number of clinical trials is steadily increasing nationwide.''
Steven B. Rash, President and CEO of American BioMed stated, ''With the inclusion of PFM, our market position significantly increases in Europe and is indicative of the strong worldwide interest in our latex free silicone balloon catheters.''
American BioMed has 11 distributors covering the North American market and 25 international distributors covering Spain, Italy, Turkey, Australia, New Zealand, Belgium, Denmark, Greece, Japan, Luxembourg, The Netherlands, Norway, Sweden, Korea, Taiwan, India, the Caribbean, United Kingdom, Venezuela, Brazil, Mexico, France and now Germany.
American BioMed, Inc. utilizes state-of-the-art technology to develop, manufacture and market minimally invasive medical devices for the treatment of cardiovascular disease. The Company's products include 100% silicone catheters, through its Cathlab subsidiary; the Evert-o-Cath™, a toposcopic catheter for site-specific drug delivery and fluid removal, the OmniCath®, an atherectomy catheter designed to remove atherosclerotic plaque from obstructed blood vessels throughout the body; and the OmniFilter, which is used to prevent blood clots from reaching various organs of the body. The Company has over twenty-five patents and 11 FDA approvals covering its product portfolio, and addresses an annual worldwide market estimated to be in excess of $10 billion.
''Safe harbor'' statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in the release are forward-looking statements that involve risks and uncertainties including, but not limited to, the results of research and development efforts, the results of pre-clinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive product development, commercialization and technological difficulties, the results of financing efforts, the effect of the Company's accounting policies, and other risks detailed in the Company's Securities and Exchange Commission filings.
SOURCE: American BioMed, Inc.
biz.yahoo.com
Regards, Jeff
|
